Combined Therapy with Mycophenolate and Cyclosporine for the Treatment of Steroid-Dependent/Resistant Nephrotic Syndrome in Children: A 9-Case Analysis—Dual Therapy in Nephrotic Syndrome
International Journal of Translational Medicine · 27.05.2026 · 6 (2) · 24
DOI: 10.3390/ijtm6020024 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Translational Medicine, online erschienen am 27.05.2026. Verfasst von Luisa Fernanda Rojas-Rosas und 9 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Steroid-resistant nephrotic syndrome (SRNS) represents a severe and challenging form of pediatric nephrotic syndrome and is associated with a high risk of progression to end-stage kidney disease. Calcineurin inhibitors (CNIs) are the standard second-line therapy; however, their use is limited by frequent relapses and long-term nephrotoxicity. Mycophenolate mofetil (MMF) offers a more favorable safety profile and a complementary mechanism of action; however, the clinical utility of combining MMF with CNIs remains largely under-explored in this population. Case Presentation: We describe a series of nine pediatric patients with steroid-resistant or steroid-dependent nephrotic syndrome who were refractory to cyclosporine monotherapy. These patients were treated with a combination regimen of cyclosporine (4–5 mg/kg/day; target trough levels of 75–150 ng/mL) and MMF (600 mg/m2/day). This therapeutic approach was associated with a reduction in corticosteroid dosage and a decrease in the annual number of relapses in most patients.
Conclusions
In this small case series of pediatric patients with corticosteroid-dependent or steroid-resistant nephrotic syndrome refractory to cyclosporine monotherapy, the addition of mycophenolate mofetil was associated with a reduction in relapse frequency and corticosteroid requirements. Despite the limited sample size, these findings suggest that combination therapy may be a therapeutic option in difficult-to-treat pediatric nephrotic syndrome and warrant further evaluation in controlled studies.
Zitieren
APA
Rojas-Rosas, L. F., Osorio, N., Navarro, M., Restrepo, M. Á., Isaza-López, M. C., Ochoa-García, C. L., Villegas-Arbeláez, E., Baquero-Rodriguez, R., Estevez, M., & Serna-Higuita, L. M. (2026). Combined Therapy with Mycophenolate and Cyclosporine for the Treatment of Steroid-Dependent/Resistant Nephrotic Syndrome in Children: A 9-Case Analysis—Dual Therapy in Nephrotic Syndrome. International Journal of Translational Medicine, 6(2), 24. https://doi.org/10.3390/ijtm6020024
Vancouver
Rojas-Rosas LF, Osorio N, Navarro M, Restrepo MÁ, Isaza-López MC, Ochoa-García CL, et al. Combined Therapy with Mycophenolate and Cyclosporine for the Treatment of Steroid-Dependent/Resistant Nephrotic Syndrome in Children: A 9-Case Analysis—Dual Therapy in Nephrotic Syndrome. International Journal of Translational Medicine. 2026;6(2):24. doi:10.3390/ijtm6020024
BibTeX
@article{RojasRosas2026,
author = {Rojas-Rosas, Luisa Fernanda and Osorio, Natalia and Navarro, Melissa and Restrepo, Miguel Ángel and Isaza-López, María Carolina and Ochoa-García, Carolina Lucia and Villegas-Arbeláez, Esteban and Baquero-Rodriguez, Richard and Estevez, Mayra and Serna-Higuita, Lina Maria},
title = {Combined Therapy with Mycophenolate and Cyclosporine for the Treatment of Steroid-Dependent/Resistant Nephrotic Syndrome in Children: A 9-Case Analysis—Dual Therapy in Nephrotic Syndrome},
journal = {International Journal of Translational Medicine},
year = {2026},
volume = {6},
number = {2},
pages = {24},
doi = {10.3390/ijtm6020024}
}
EUVIMED